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Abstract 
This research involves preparation of mouth dissolving tablets of solid dispersions of Domperidone by direct 
compression method using various concentrations of superdisintegrants in combination i.e. Croscarmellose Sodium 
and crospovidone. For optimization, a 32 (two-factor three-level) factorial design is being used in which 2 factors 
were evaluated, each at 3 levels and experimental trials were performed at all 9 possible combinations for every four 
selected solid dispersion batches (9x4=36 formulations + one blank). The amount of Croscarmellose Sodium (X1) 
and crospovidone (X2) was selected as independent variables. The disintegration time, percentage friability and 
percent drug release were selected as dependent variables. All the active powder blends were evaluated for pre-
compression parameters (viz. angle of repose, Carr’s index, Hausner ratio, etc.) and the tablets were evaluated for 
post-compression parameters (viz. weight variation, hardness, and friability, wetting time, disintegration time, water 
absorption ratio, and in vitro drug release studies). Optimization was done using the software (Design Expert® 
11.0.4), predicted responses of which were validated.  
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Introduction 
 
Drugs are rarely administered in their original pure 
state due to various issues like stability, proper dose 
strength, etc. They are administered in various dosage 
forms after converting it into a suitable stable 
formulation [1]. The aim of dosage form is to 
administer a drug at a therapeutic concentration to a 
particular site of action for a specified period of time 
[2]. Oral routes of drug administration are widely used 
up to 50-60% of total dosage forms [3]. Several orally 
administered drugs have a less bioavailability due to 
their poor water solubility. In Biopharmaceutics 
classification system, drugs with decreased aqueous or 
water solubility, slow dissolution rate and increased 
membrane permeability are categorized as Class II 
drug [4].  
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Since for BCS class II drugs, rate determining step is 
release of drug from the dosage form and its solubility 
in the gastric fluid, so increasing the solubility leads to 
increases the bioavailability for BCS class II drugs 
[5,6,7,8,9]. Solid dispersion is one of the many 
techniques available to enhance drug dissolution and 
bioavailability of poorly water-soluble drugs. Further, 
such formulations can be dispensed in the form of fast 
dissolving tablets which disintegrate and/or dissolve 
rapidly in saliva; thus may help in improving the 
bioavailability of such drugs. 
When the solid dispersion comes in contact with the 
aqueous medium, the inert carrier or polymer dissolves 
quickly thereby releasing the drug, the increased 
surface area produces a higher dissolution rate thus 
increasing the bioavailability of the poorly soluble 
drug. Vomiting is the common problem for all the age 
groups. Domperidone, an antiemetic and prokinetic is 
one of the effectively used in vomiting / motion 
sickness, having less side effects, with half life of 7.5 
hours but poorly soluble in water and hence less 
bioavailable [10]. 
The purpose of this research is to prepare solid 
dispersions of Domperidone, an antiemetic drug and 
employing them with superdisintegrants in different 
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concentrations in the development of mouth dissolving 
tablets. The superdisintegrants will use in this study are 
croscarmellose sodium and crospovidone. Tablets will 
be prepared by direct compression technique and will 
be evaluated for uniformity of weight, thickness, 
hardness, friability, disintegration time (DT) and 
dissolution study. Factorial design will use for the 
optimization of tablets and to see the effect of 
concentration of superdisintegrants in the development 
of MDTs.  
 
Materials & Methods 
Materials. Domperidone (API), Polyethylene Glycol 
(PEG-4000, 6000), Polyvinyl Pyrrolidone (PVP K-30, 
90), Croscarmellose Sodium, Crospovidone, Mannitol, 
Aspartame, Microcrystalline Cellulose was obtained as 
a gift sample from Wockhardt Research Centre, 
Aurangabad, Maharashtra, India. Talc, Magnesium 
Stearate, Lactose were procured from R.S. Enterprises, 
Jaipur, India manufactured by Central Drug House (P) 
Ltd – CDH, New Delhi, India. All chemicals used were 
of analytical grade. 
Methods  
Preparation of solid dispersions of Domperidone 
Solid dispersions (SDs) of Domperidone (DOM) 
prepared by fusion method with polymers PEG (4000 
and 6000) and PVP (K30 and K90) in drug to polymer 
ratio 1:4 used for preparing mouth dissolving tablets 
[11,12].  
Preparation of Mouth Dissolving Tablets of 
Domperidone Solid Dispersion by Direct 
Compression Method 
Preliminary trial batch were prepared by direct 
compression technique using single punch tablet 
machine. Thirty Seven MDT formulations each 
weighing 200 mg, were prepared by using solid 
dispersion of Domperidone Maleate (equivalent to 
10mg in each tablet) along with a mixture of 
Croscarmellose Sodium and Crospovidone, at different 
concentrations 2% to 8% w/w. Batches were prepared 
by mixing combination of Superdisintegrants, 
AvicelPH102, Mannitol and Lactose in a glass mortar 
and pestle and were lubricated with 2% w/w Talc and 
2% w/w Magnesium stearate. Finally mixed powder 
blends were converted into tablets using a single-punch 
tablet compression machine.  
Solid dispersions SDP414, SDP614, SDK314 and 
SDK914 were used for formulation of mouth 
dissolving tablets. The composition and codes of 
formulations are shown in table 1 to 4. Batch D1 
consist of pure Domperidone without using its solid 
dispersion. 
Table 1: Composition and codes of SD P414 mouth dissolving tablets 
Ingredient (mg) Formulation Codes 
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
SD P414*(DOM) - 50 50 50 50 50 50 50 50 50 
Domperidone 10 - - - - - - - - - 
Croscarmellose Sodium - 2 2 2 4 4 4 6 6 6 
Crospovidone - 2 4 6 2 4 6 2 4 6 
Mannitol 20 10 10 10 10 10 10 10 10 10 
Aspartame 1 1 1 1 1 1 1 1 1 1 
Talc 4 4 4 4 4 4 4 4 4 4 
Magnesium stearate 4 4 4 4 4 4 4 4 4 4 
AvicelPH102 30 30 30 30 30 30 30 30 30 30 
Lactose 131 97 95 93 95 93 91 93 91 89 
* Solid Dispersion containing PEG-4000, Drug to Polymer Ratio: 1:4 
 
Table 2: Composition and codes of SD P614 mouth dissolving tablets 
Ingredient (mg) Formulation Codes 
D11 D12 D13 D14 D15 D16 D17 D18 D19 
SD P614#(DOM) 50 50 50 50 50 50 50 50 50 
Croscarmellose Sodium 2 2 2 4 4 4 6 6 6 
Crospovidone 2 4 6 2 4 6 2 4 6 
Mannitol 10 10 10 10 10 10 10 10 10 
Aspartame 1 1 1 1 1 1 1 1 1 
Talc 4 4 4 4 4 4 4 4 4 
Magnesium stearate 4 4 4 4 4 4 4 4 4 
AvicelPH102 30 30 30 30 30 30 30 30 30 
Lactose 97 95 93 95 93 91 93 91 89 
# Solid Dispersion containing PEG-6000, Drug to Polymer Ratio: 1:4 
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Table 3: Composition and codes of SD K314 mouth dissolving tablets 
Ingredient (mg) Formulation Codes 
D20 D21 D22 D23 D24 D25 D26 D27 D28 
SD K314$(DOM) 50 50 50 50 50 50 50 50 50 
Croscarmellose Sodium 2 2 2 4 4 4 6 6 6 
Crospovidone 2 4 6 2 4 6 2 4 6 
Mannitol 10 10 10 10 10 10 10 10 10 
Aspartame 1 1 1 1 1 1 1 1 1 
Talc 4 4 4 4 4 4 4 4 4 
Magnesium stearate 4 4 4 4 4 4 4 4 4 
AvicelPH102 30 30 30 30 30 30 30 30 30 
Lactose 97 95 93 95 93 91 93 91 89 
$ Solid Dispersion containing PVP-K30, Drug to Polymer Ratio: 1:4 
 
Table 4: Composition and codes of SD K914 mouth dissolving tablets 
Ingredient (mg) Formulation Codes 
D29 D30 D31 D32 D33 D34 D35 D36 D37 
SD K914^(DOM) 50 50 50 50 50 50 50 50 50 
Croscarmellose Sodium 2 2 2 4 4 4 6 6 6 
Crospovidone 2 4 6 2 4 6 2 4 6 
Mannitol 10 10 10 10 10 10 10 10 10 
Aspartame 1 1 1 1 1 1 1 1 1 
Talc 4 4 4 4 4 4 4 4 4 
Magnesium stearate 4 4 4 4 4 4 4 4 4 
AvicelPH102 30 30 30 30 30 30 30 30 30 
Lactose 97 95 93 95 93 91 93 91 89 
^ Solid Dispersion containing PVP-K90, Drug to Polymer Ratio: 1:4 
 
Evaluation of Powder Blends: All formulation 
powder bland batches were evaluated for 
precompression studies viz. angle of repose, bulk 
density, tapped density, Carr’s consolidation index, and 
Hausner’s ratio as per the official methods [13, 14, 15]. 
Evaluation of Compressed Tablets 
Tablet Thickness 
From each batch ten tablets were taken of and their 
thickness was recorded using Eureka Thickness Tester. 
The data is shown in Table 5. 
Hardness 
Hardness of the MDT of each batch was determined 
using Monsanto hardness tester. It is expressed in 
kg/cm2. The data is shown in Table 5. 
Weight Variation 
All the batches of compressed MDT’s were subjected 
to weight variation test, as per IP-2010 [16]. Twenty 
tablets were taken and weighted individually; their 
average weight was calculated and compared with the 
individual tablet weight to notice the variation in tablet 
weights. The data is shown in Table 5. 
Friability 
Friability of tablets was determined using Roche 
friabilator. Sample of 20 pre-weighed MDTs were 
placed in a friabilator and revolve at a speed of 25 rpm  
 
for 4 min [17]. Now dust removed from the tablets, 
weighed again, and percentage weight loss (friability) 
was calculated. 
% Friability =   1 - 
𝑊𝑜
𝑊
      x 100        ............Eq.1 
 
Where, W0 is initial weight of the tablets before the test 
and W is the weight of the tablets after test. Results are 
presented in Table 5. 
Wetting Time 
Five circular tissue papers were placed in a petridish of 
10 cm diameter. Ten milliliters of phosphate buffer pH 
6.8 containing a water-soluble dye (Amaranth), was 
added to the petridish to check complete wetting of the 
tablet surface. A tablet was cautiously placed on the 
surface of the tissue paper in the petridish containing 
dye solution at 25°C and wetting time was noted using 
a stopwatch as the time required for dye solution to 
reach the upper surface of the tablets and to completely 
wet. These results were carried out in repetition of 
three [18,19]. The data is shown in Table 5.  
In vitro Disintegration Test [20,21] 
Bi et al. recommended the use of a modified 
dissolution apparatus (a paddle method), in place of the 
conventional disintegration apparatus [20]. The 
% Friability = {1 - 
𝑊𝑜
𝑊
} x 100 ...Eq.1 
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disintegration time of MDTs is determined by means of 
the disintegration test for conventional tablets that is 
described in the official monographs.  
 
Figure 1: Modified Dissolution Apparatus for Disintegration of MDT’s [20] 
In this study, 900 ml of phosphate buffer pH 6.8 
maintained at 37°C was used as the disintegration fluid 
and a paddle at 100 rpm used as stirring element. 
Disintegration time was noted when the tablet 
disintegrated and passed completely through the screen 
of the sinker (height 3–3.5 mm, width 3.5–4 mm and 
submersed at a depth of 8.5 cm from the top with the 
help of a hook). 
Content Uniformity [22]:  
Randomly selected twenty tablets from each trial batch 
were weighed and then powdered in a glass mortar 
with pestle. The weight equivalent to 10 mg of 
powdered DOM was taken and dissolved in 10 ml of 
methanol in volumetric flask. The volume was then 
adjusted to 100 ml with phosphate buffer pH 6.8. An 
aliquot of 2.5 ml of the above solution was taken and 
diluted to 10 ml with phosphate buffer pH 6.8 in 
separate volumetric flask. The absorbance of above 
sample was determined spectrophotometrically at 284 
nm and drug content was determined using calibration 
curve. The mean value and standard deviation of all the 
formulations were calculated.  
%Drug Content =Sample Absorbance/ Standard 
Absorbance x 100.............Eq.2 
In vitro Release study [23,24]:  
The in vitro release studies of all the formulations were 
carried out using USP type II dissolution test apparatus. 
The tablets were placed in dissolution bowls containing 
900 ml of phosphate buffer pH 6.8 maintained at 37ºC 
± 0.5 and stirred at 50 rpm. Samples (5 ml) were 
collected by manual programming at different time 
intervals (1, 2, 4, 6, 8, 10, 15 min) and replaced with 
fresh dissolution medium. The absorbance was 
determined spectrophotometrically at 284 nm. 
Comparison of dissolution profiles were constructed as 
shown in fig. 2 to 5. Cumulative drug release was 
calculated on the basis of mean amount of DOM 
present in the respective tablet by the formula: 
Amount released (mg) = 
1000
factorDilution   eBath volum ion Concentrat  .........Eq.3 
Percent drug release (PDR) = 
100
content Drug
releasedAmount 

...............................Eq.4 
Factorial Design: 
To see the effect of superdisintegrants on dependent 
variables and to know the actual amount of 2 
superdisintegrants on the desirable properties of mouth 
dissolving tablets a 32 randomized full factorial design 
was used in which 2 factors were evaluated, each at 3 
levels and experimental trials were performed at all 9 
possible combinations for every four selected solid 
dispersion batches (9x4=36 formulations + one blank 
means without superdisintegrants) [25,26]. The amount 
of Croscarmellose Sodium (X1) and crospovidone (X2) 
was selected as independent variables. The 
disintegration time, percentage friability and percent 
drug release were selected as dependent variables. 
Following polynomial equation is used to see the effect 
of independent variables on dependent variables 
Y =b0+b1X1+b2X2+b11X1X1+b22X2X2+ b12X1X2.....Eq.5 
Where, Y is the dependent variable, b0 is the arithmetic 
mean response of the 9 runs, and b1 is the estimated 
coefficient for the factor X1. The main effects (X1 and 
X2) represent the average result of changing 1 factor at 
a time from its low to high value. The interaction terms 
(X1X2) show how the response changes when 2 factors 
are simultaneously changed. The polynomial terms 
(X1X1 and X2X2) are included to investigate 
nonlinearity. 
Result & Discussion 
Pre-compression Evaluation 
The results of bulk density and tapped density ranged 
from 0.45 ± 0.02 to 0.61 ± 0.01 and 0.54 ± 0.02 to 0.70 
± 0.04 respectively. The results of angle of repose 
(18.12 ± 0.11 to 26.36 ± 0.15) indicated good flow 
properties which were further supported by Carr’s 
index (12.86 to 17.12) and Hausner’s ratio data (1.15 to 
1.21). Results are shown in table 
Post-compression Evaluation Average tablet 
thickness (Table No. 5) was found to be consistent 
throughout the batch. Tablet thickness ranges between 
4.01mm to 4.05mm. As these tablets are rapidly 
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disintegrating.  Tablet hardness ranges between 2.12 
kg/cm2 to 2.83 kg/cm2. Uniformity of weight of the 
MDTs was assessed and the average weight for all 
formulations was found to be between 198-203 mg 
which was within in the prescribed limits i.e. ±7.5% 
(185 to 215 mg).The wetting time in all the formulation 
was very fast except D1 (100 seconds) which may be 
due to absence of solid dispersion of Domperidone. It 
ranges between 24 to 45 seconds which is depend on 
the concentration of superdisintegrants in the tablets. 
The friability of all formulations was found to be less 
than 1.0%. Friability was found to be in the range of 
0.2- 0.54%. Disintegration time of prepared MDTs was 
in the range of 20-45 seconds. The disintegration time 
was found to follow in the following order; 
Crosscarmellose<Crospovidone and PVP<PEG. As the 
concentration of superdisintegrants in the formulations 
was increased the disintegration time was found to 
decrease. The percent drug content of the tablets was 
found between 96.40% to 100.72% of Domperidone. 
Drug content of all the formulations was found to be 
within the limits. 
Table 5: Evaluation of Post-compression/Tablet parameters 
Form. 
Code 
Uniformity of 
Thickness (mm) (n 
=10) 
Diameter (mm) 
(n = 3) 
Hardness  (kg/cm2) 
(n=3) 
Weight 
Variation(mg) (n 
= 20)  
Wetting time 
(s) (n=5) 
Drug Content 
Uniformity (n = 
10) (%) 
D1 4.04 ± 0.02 8.02 ± 0.01 2.69 ± 0.02 202 ± 3.34 98-103 97.56 ± 0.25 
D2 4.02 ± 0.01 8.05 ± 0.02 2.25 ± 0.03 201 ± 2.60 41-45 99.71 ± 0.12 
D3 4.03 ± 0.01 8.00 ± 0.01 2.47 ± 0.01 203 ± 3.70 39-42 97.04 ± 0.23 
D4 4.01 ± 0.03 8.04 ± 0.01 2.53 ± 0.03 202 ± 2.95 36-40 98.85 ± 0.56 
D5 4.01 ± 0.02 8.02 ± 0.01 2.29 ± 0.01 199 ± 3.67 40-44 98.29 ± 0.78 
D6 4.00 ± 0.06 8.03 ± 0.02 2.45 ± 0.04 201 ± 3.12 35-39 99.62 ± 0.28 
D7 4.02 ± 0.04 8.03 ± 0.03 2.23 ± 0.02 200 ± 2.15 33-37 98.47 ± 0.45 
D8 4.03 ± 0.02 8.04 ± 0.01 2.62 ± 0.03 202 ± 1.82 31-35 97.33 ± 0.12 
D9 4.05 ± 0.01 8.01 ± 0.03 2.51 ± 0.02 201 ± 2.16 28-32 99.24 ± 0.45 
D10 4.04 ± 0.02 8.02 ± 0.01 2.59 ± 0.02 202 ± 2.45 26-30 97.67 ± 0.67 
D11 4.02 ± 0.01 8.05 ± 0.02 2.15 ± 0.03 201 ± 2.12 40-44 99.82 ± 0.78 
D12 4.03 ± 0.01 8.00 ± 0.01 2.37 ± 0.01 203 ± 2.70 38-41 97.15 ± 0.13 
D13 4.01 ± 0.03 8.04 ± 0.01 2.43 ± 0.03 202 ± 1.95 35-39 98.96 ± 0.34 
D14 4.01 ± 0.02 8.02 ± 0.01 2.49 ± 0.01 199 ± 2.57 39-43 98.4 ± 0.89 
D15 4.00 ± 0.06 8.03 ± 0.02 2.35 ± 0.04 201 ± 1.82 34-38 99.73 ± 0.09 
D16 4.02 ± 0.04 8.03 ± 0.03 2.13 ± 0.02 200 ± 2.15 32-36 98.58 ± 0.35 
D17 4.03 ± 0.02 8.04 ± 0.01 2.52 ± 0.03 202 ± 1.82 30-34 97.44 ± 0.25 
D18 4.05 ± 0.01 8.01 ± 0.03 2.51 ± 0.02 201 ± 1.96 27-31 99.35 ± 0.29 
D19 4.04 ± 0.02 8.02 ± 0.01 2.79 ± 0.02 202 ± 2.34 25-29 97.5 ± 0.12 
D20 4.03 ± 0.01 8.03 ± 0.03 2.65 ± 0.03 201 ± 2.80 40-44 99.65 ± 0.25 
D21 4.01 ± 0.03 8.04 ± 0.01 2.57 ± 0.01 203 ± 2.73 38-41 96.98 ± 0.26 
D22 4.01 ± 0.02 8.01 ± 0.03 2.43 ± 0.03 202 ± 2.95 35-39 98.79 ± 0.74 
D23 4.00 ± 0.06 8.02 ± 0.01 2.39 ± 0.01 198 ± 1.87 39-43 98.23 ± 0.87 
D24 4.02 ± 0.04 8.05 ± 0.02 2.25 ± 0.04 201 ± 2.72 34-38 99.56 ± 0.43 
D25 4.03 ± 0.02 8.00 ± 0.01 2.23 ± 0.02 200 ± 2.35 32-36 98.41 ± 0.32 
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D26 4.05 ± 0.01 8.04 ± 0.01 2.12 ± 0.03 202 ± 2.52 30-34 97.27 ± 0.87 
D27 4.04 ± 0.02 8.02 ± 0.01 2.31 ± 0.02 201 ± 2.56 27-31 99.18 ± 0.47 
D28 4.02 ± 0.01 8.03 ± 0.02 2.49 ± 0.02 202 ± 2.34 25-29 97.59 ± 0.87 
D29 4.03 ± 0.01 8.03 ± 0.03 2.55 ± 0.03 201 ± 1.90 39-43 99.74 ± 0.98 
D30 4.01 ± 0.03 8.04 ± 0.01 2.67 ± 0.01 203 ± 2.70 37-40 97.07 ± 0.65 
D31 4.01 ± 0.02 8.01 ± 0.03 2.83 ± 0.03 202 ± 2.75 34-38 98.88 ± 0.43 
D32 4.00 ± 0.06 8.02 ± 0.01 2.19 ± 0.01 198 ± 2.87 38-42 98.32 ± 0.98 
D33 4.02 ± 0.04 8.05 ± 0.02 2.35 ± 0.04 201 ± 2.92 33-37 99.65 ± 0.25 
D34 4.03 ± 0.02 8.00 ± 0.01 2.53 ± 0.02 200 ± 2.45 31-35 98.5 ± 0.21 
D35 4.05 ± 0.01 8.04 ± 0.01 2.62 ± 0.03 202 ± 1.82 29-33 97.36 ± 0.12 
D36 4.04 ± 0.02 8.02 ± 0.01 2.51 ± 0.02 201 ± 2.16 26-30 99.27 ± 0.25 
D37 4.02 ± 0.01 8.03 ± 0.02 2.65 ± 0.03 201 ± 2.80 24-28 99.65 ± 0.25 
 
 
Fig. 2: Comparison of % Drug release of MDT prepared from Plain Domperidone (D1) and SD P414 (D2-
D10) 
 
 
Fig. 3: Comparison of % Drug release of MDT prepared from SD P614 (D11-D19) 
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Fig. 4: Comparison of % Drug release of MDT prepared from SD K314 (D20-D28) 
 
 
Fig. 5: Comparison of % Drug release of MDT prepared from SD K914 (D29-D37) 
Optimization of Superdisintegrants Concentration: 
Effect of Superdisintegrants on in vitro 
Disintegration Time 
The response surface plot demonstrated the effect of 
amount of Croscarmellose Sodium (X1) and 
crospovidone (X2) on disintegration time (DT) (Y1). 
The polynomial equation indicated that disintegration 
time was significantly decreased from 39 → 33 → 28 
(of SD P414), 37 → 31 → 26 (of SD P614), 38 → 34 
→ 27 (of SD K314), 36 → 28 → 24 (of SD K914);  
and from 34 → 30 → 25 (of SD P414), 33 → 28 → 23 
(of SD P614), 35 → 29 → 22 (of SD K314), 30 → 25 
→ 20 (of SD K914) at low and high level of 
Croscarmellose Sodium, respectively, as the 
concentration of the crospovidone was increased. The 
DT value was changed from 39 → 36 → 34 (of SD 
P414), 37 → 35 → 33 (of SD P614), 38 → 37 → 35 
(of SD K314), 36 → 32 → 30 (of SD K914); and from 
28 → 27 → 25 (of SD P414), 26 → 24 → 23 (of SD 
P614),  27 → 24 → 22 (of SD K314),  24 → 22 → 20 
(of SD K914) at low and high levels of crospovidone, 
respectively, as the concentration of Croscarmellose 
Sodium was increased. Increased concentration of 
crospovidone has significant effect on DT at low 
concentration of Croscarmellose Sodium, whereas it 
has a little effect on DT at high concentration of 
Croscarmellose Sodium. Increased concentration of 
Croscarmellose Sodium exhibited a random effect on 
DT value at low level of crospovidone and little effect 
at high level of crospovidone.  
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Effect of Superdisintegrants on Friability 
The response surface plot demonstrated the effect of 
amount of Croscarmellose Sodium (X1) and 
crospovidone (X2) on Friability (Y2). The polynomial 
equation indicated that friability was decreased from 
0.35 → 0.30 → 0.25 (of SD P414), 0.32 → 0.27 → 
0.22 (of SD P614), 0.33 → 0.28 → 0.23 (of SD K314), 
0.30 → 0.25 → 0.20 (of SD K914); and from 0.54 → 
0.50 → 0.45 (of SD P414), 0.51 → 0.48 → 0.42 (of SD 
P614), 0.52 → 0.49 → 0.44 (of SD K314), 0.45 → 
0.40 → 0.39 (of SD K914),  at low and high level of 
Croscarmellose Sodium, respectively, as the 
concentration of the crospovidone was increased. The 
friability value was increased from 0.35 → 0.49 → 
0.54 (of SD P414), 0.32 → 0.45 → 0.51 (of SD P614), 
0.33 → 0.46 → 0.52 (of SD K314), 0.30 → 0.43 → 
0.49 (of SD K914); and from 0.25 → 0.34 → 0.45 (of 
SD P414), 0.22 → 0.31 → 0.42 (of SD P614), 0.23 → 
0.32 → 0.44 (of SD K314), 0.20 → 0.30 → 0.40 (of 
SD K914), at low and high levels of crospovidone, 
respectively, as the concentration of Croscarmellose 
Sodium was increased. Increased concentration of 
crospovidone significantly decreases friability at low & 
high concentration of Croscarmellose Sodium. 
Increased concentration of Croscarmellose Sodium 
exhibited insignificant increases in friability at low & 
high level of crospovidone.  
 
Effect of Superdisintegrants on Percent Drug 
Release 
The response surface plot demonstrated the effect of 
amount of Croscarmellose Sodium (X1) and 
crospovidone (X2) on Percent Drug Release (PDR) 
(Y3). The polynomial equation indicated that PDR was 
increased from 90.5 → 93.8 → 96.8 (of SD P414), 91.1 
→ 94.4 → 97.4 (of SD P614), 91.6 → 94.9 → 97.9 (of 
SD K314), 92.4 → 95.7 → 98.7 (of SD K914); and 
from 92.6 → 94.6→ 97.2 (of SD P414), 93.2 → 96.9→ 
98.2 (of SD P614), 93.7 → 97.4→ 98.8 (of SD K314), 
94.5 → 98.2→ 99.6 (of SD K914), at low and high 
level of Croscarmellose Sodium, respectively, as the 
concentration of the crospovidone was increased. The 
PDR was increased from 90.5 → 91.3 → 92.6 (of SD 
P414), 91.1 → 91.9 → 93.2 (of SD P614), 91.6 → 92.4 
→ 93.7 (of SD K314), 92.4 → 93.3 → 94.5 (of SD 
K914); and from 96.8 → 97 → 97.2 (of SD P414), 97.4 
→ 97.6 → 98.2 (of SD P614), 97.9 → 98.1 → 98.8 (of 
SD K314), 98.7 → 98.9 → 99.6 (of SD K914), at low 
and high levels of crospovidone, respectively, as the 
concentration of Croscarmellose Sodium was 
increased. Increased concentration of crospovidone 
significantly increases PDR at low & high 
concentration of Croscarmellose Sodium. Increased 
concentration of Croscarmellose Sodium exhibited 
little increases in PDR at low & high level of 
crospovidone.  
 
Coded values  Actual values (mg) 
X1 X2 
-1 2 2 
0 4 4 
1 6 6 
 
Table 6: 32 Full Factorial Design Layout 
Batch Codes Variable Levels in Coded 
Form 
Disintegration 
Time 
% Friability % Drug 
Release 
X1 X2 DT (sec) F (%) Disso (%) 
32 Full Factorial Design Layout (MDT of SD P414) 
D2 -1 -1 39 0.35 90.5 
D3 -1 0 33 0.3 93.8 
D4 -1 1 28 0.25 96.8 
D5 0 -1 36 0.49 91.3 
D6 0 0 32 0.39 94.6 
D7 0 1 27 0.34 97.0 
D8 1 -1 34 0.54 92.6 
D9 1 0 30 0.5 94.6 
D10 1 1 25 0.45 97.2 
OPT 0.09 0.22 30.56 0.4 95.0 
32 Full Factorial Design Layout  
D11 -1 -1 37 0.32 91.1 
D12 -1 0 31 0.27 94.4 
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D13 -1 1 26 0.22 97.4 
D14 0 -1 35 0.45 91.9 
D15 0 0 30 0.36 95.2 
D16 0 1 24 0.31 97.6 
D17 1 -1 33 0.51 93.2 
D18 1 0 28 0.48 96.9 
D19 1 1 23 0.42 98.2 
OPT 0.19 -0.17 30.24 0.4 95.0 
32 Full Factorial Design Layout (MDT of SD K314) 
D20 -1 -1 38 0.33 91.6 
D21 -1 0 34 0.28 94.9 
D22 -1 1 27 0.23 97.9 
D23 0 -1 37 0.46 92.4 
D24 0 0 32 0.38 95.7 
D25 0 1 24 0.32 98.1 
D26 1 -1 35 0.52 93.7 
D27 1 0 29 0.49 97.4 
D28 1 1 22 0.44 98.8 
OPT 0.13 -0.01 31.58 0.4 95.87 
32 Full Factorial Design Layout (MDT of SD K914) 
D29 -1 -1 36 0.3 92.4 
D30 -1 0 28 0.25 95.7 
D31 -1 1 24 0.2 98.7 
D32 0 -1 32 0.43 93.3 
D33 0 0 26 0.38 96.5 
D34 0 1 22 0.3 98.9 
D35 1 -1 30 0.49 94.5 
D36 1 0 25 0.45 98.2 
D37 1 1 20 0.4 99.6 
OPT -0.002≈0 -0.52 29.02 0.39 94.99 
Table 7: Summary of Results of Regression Analysis (MDT of SDP414) 
Response (full model) b0 b1 b2 b12 b11 b22 
MDT of SD P414 
Disintegration Time 31.778 -1.833 -4.833 0.500 -0.167 -0.167 
% Friability 0.402 0.098 -0.057 0.003 -0.008 0.007 
% Drug Release 94.367 0.550 2.767 -0.425 -0.050 -0.100 
MDT of SD P614 
Disintegration Time 29.667 -1.667 -5.333 0.250 0.000 0.000 
% Friability 0.372 0.100 -0.055 0.003 -0.003 0.002 
% Drug Release 95.300 0.900 2.833 -0.325 0.300 -0.600 
MDT of SD K314 
Disintegration Time 31.778 -2.167 -6.167 -0.500 -0.167 -1.167 
% Friability 0.387 0.102 -0.053 0.005 -0.005 0.000 
% Drug Release 95.789 0.917 2.850 -0.300 0.317 -0.583 
MDT of SD K914 
Disintegration Time 26.000 -2.167 -5.333 0.500 0.500 1.000 
% Friability 0.374 0.098 -0.053 0.003 -0.022 -0.007 
% Drug Release 96.611 0.917 2.833 -0.300 0.283 -0.567 
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Fig. 6: Overlay Plot for Predicted Optimized Formulation of SD P414 
 
Fig. 7: Overlay Plot for Predicted Optimized Formulation of SD P614 
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Fig. 8: Contour Plot for Predicted Optimized Formulation of SD K314 
 
Fig. 9: Overlay Plot for Predicted Optimized Formulation of SD K915 
 
Conclusion 
Mouth dissolving tablets of Domperidone solid 
dispersion (prepared using four different combinations 
of drug with two different polymers in ratio 1:4) were 
formulated and optimized using 32 factorial design. 
Two independent variables i.e.  amount of 
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Croscarmellose Sodium and crospovidone at three 
levels were selected on the basis of preliminary studies. 
As the concentration of superdisintegrants in the 
formulations was increased the disintegration time was 
found to decrease. It was found that increased 
concentration of crospovidone cause decrease in 
disintegration time and increased percent drug release 
and has very little effect of increasing concentration of 
croscarmellose sodium. All the formulations show 
maximum (>90%) drug release in minimum time. 
Design-Expert® (11.0.4) software was used for design 
& optimization of batches and response surface plots & 
contour plots were drawn, and optimum formulations 
were selected by desirability plots. For various 
response variables, polynomial mathematical models 
were generated using multiple regression analysis, and 
found to be statistically significant (𝑃<0.05). 
Optimized formulations were further used for 
preparing optimized mouth dissolving tablets. 
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